Black Diamond Therapeutics, Inc. (BDTX)
| Market Cap | 171.33M +87.8% |
| Revenue (ttm) | n/a |
| Net Income | -43.21M |
| EPS | -0.76 |
| Shares Out | 57.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,663,279 |
| Open | 2.720 |
| Previous Close | 2.720 |
| Day's Range | 2.700 - 3.150 |
| 52-Week Range | 1.532 - 4.940 |
| Beta | 3.34 |
| Analysts | Strong Buy |
| Price Target | 9.67 (+223.41%) |
| Earnings Date | May 7, 2026 |
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price target is $9.67, which is an increase of 223.41% from the latest price.
News
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase...
Black Diamond price target raised to $11 from $10 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $11 from $10 and keeps a Buy rating on the shares. Published first on
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush
Wedbush raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $14 from $13 and keeps an Outperform rating on the shares following quarterly results and updates regarding silevertinib
Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)
“We continue to focus on advancing silevertinib for the treatment of patients with EGFRm NSCLC and EGFR altered GBM,” said Mark Velleca, president and CEO of Black Diamond Therapeutics (BDTX).
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Silevertinib, a fourth-generation EGFR inhibitor, shows strong efficacy and CNS activity in non-classical EGFR NSCLC and is advancing into a pivotal GBM trial. Key PFS data in NSCLC are expected in Q2 2024, with GBM trial enrollment starting soon and results anticipated in 2028.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler
Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $8 from $9 and keeps an Overweight rating on the shares. Following a flurry
Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Silevertinib’s Phase II data in non-classical EGFR-mutant lung cancer showed a 60% response rate and strong CNS activity, with durability and PFS data expected in Q2 2026. Plans include FDA engagement, a pivotal trial, and a Phase II GBM study, supported by a strong financial runway.
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy without a price target While the headline overall response rate in the silevertinib 1L non-classical EGF...
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy.
Black Diamond Therapeutics Transcript: Study Update
Silevertinib demonstrated a 60% response rate and robust CNS activity in frontline NSCLC patients with non-classical EGFR mutations, with efficacy maintained after dose reductions. A randomized phase II trial in newly diagnosed GBM patients with EGFR variant 3 will launch, focusing on high unmet need and leveraging silevertinib's strong brain penetrance.
Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib
Black Diamond Therapeutics (BDTX) announced topline data from its Phase 2 trial of silevertinib in frontline non-small cell lung cancer, NSCLC, patients with non-classical epidermal growth factor rece...
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing...
Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
Piper Sandler assumed coverage of Black Diamond Therapeutics (BDTX) with an Overweight rating and $9 price target Black Diamond is advancing lead asset silevertinib, a “potentially best-in-class” four...
Black Diamond Therapeutics files $500M mixed securities shelf
17:22 EST Black Diamond Therapeutics (BDTX) files $500M mixed securities shelf
Black Diamond Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Silevertinib is advancing as a brain-penetrant EGFR inhibitor for non-small cell lung cancer and glioblastoma, targeting a broad range of mutations with promising early efficacy and tolerability. Key data updates and partnership decisions are expected in the coming quarters.
Black Diamond Therapeutics Transcript: Stifel 2025 Healthcare Conference
Silevertinib, a brain-penetrant EGFR inhibitor, is advancing in phase 2 for non-classical EGFR-mutant lung cancer and glioblastoma, with key data expected this quarter. The drug targets a broad mutation spectrum, with a $2B+ market opportunity and pivotal phase 3 planned next year.
Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)
“We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial in newly diagnosed patients with EGFRm NSCLC,” said Mark Velleca, M.D., Ph.D.,
Black Diamond Therapeutics sees cash runway into 4Q27
Black Diamond ended the third quarter of 2025 with approximately $135.5 million in cash, cash equivalents and investments, which the Company believes is sufficient to fund its anticipated operating ex...
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Black Diamond Therapeutics resumed with a Buy at Stifel
Stifel analyst Laura Prendergast resumed coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $8 price target The firm says the company’s silevertinib “checks all the main boxes”
Black Diamond Therapeutics initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $6 price target Lead program silevertinib has already delivered “encouraging” preliminary efficacy in Phas...